A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
A Randomized, Double-blind, Placebo-controlled, Multicenter, 12 Months Treatment Duration, Dose Finding Study, to Evaluate Efficacy, Safety and Pharmacodynamics of QCZ484 in Mild to Moderate Hypertensive Patients
Sponsor: Novartis Pharmaceuticals
This PHASE2 trial investigates Hypertension and is currently actively recruiting participants. Novartis Pharmaceuticals leads this study, which shows 7 recorded versions since 2025 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Change History
7 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2
-
Sep 2025 — Jan 2026 [monthly]
Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Mar 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Andalusia, United States, Austin, United States, Baltimore, United States, Baton Rouge, United States, Bedford, United States, Berlin, United States, Binghamton, United States, Birmingham, United States, Brandon, United States, Chicago, United States and 63 more location s